Sign in
CompletedNo phase

Role of ARMA in Selective Subset of Refractory GERD Patients.

Key facts

Who runs it
Asian Institute of Gastroenterology, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
30 Mar 2023
Ended
30 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ARMA
  • UGI Endoscopy
Record updated
4 April 2025

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Normal Upper Gastrointestinal endoscopy And
  • 24 hour pH Impedance: AET < 6%, More than 80 refluxes
  • Patients who are willing to give consent for the procedure

Who cannot take part

  • Previous esophageal or gastric surgery
  • Large Hiatal hernia >3cm
  • Lower esophageal sphincter (LES) pressure >15 mm Hg
  • Paraesophageal hernia
  • GE flap valve grade IV (Hill's classification)
  • Barretts esophagus
  • Esophageal dysmotility
  • ASA physical status >II
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).

The 2 groups in the trial

  • ARMA GroupExisting treatment, for comparison

    All patients in this group will undergo Anti-reflux mucosal ablation using upper gastrointestinal endoscopy. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.

    Treatment: ARMA

  • Sham GroupSham treatment, for comparison

    UGI Endoscopy will be performed under Propofol based sedation with scope kept inside for at least 5 minutes.

    Treatment: UGI Endoscopy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of ARMA in Selective Subset of Refractory GERD Patients- A Randomized Sham Control Trial.
Record updated
4 April 2025